Page 8 - மீடியா பிரான்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 with product launch anticipated in 2021 1 Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type 2 diabetes, expected to commence in H2 2021 PXL065 Phase 2 study ongoing with completion of recruitment expected in mid-2021 and topline data readout in mid-2022 Imeglimin and PXL065 preclinical and clinical data published in peer reviewed journals; PXL770 data accepted for oral and poster presentations at an upcoming scientific conference

United statesSouth koreaArthur rouillMerck seronoThomas kuhnSumitomo dainippon pharmaValeria fisherCatherine davidAdditional development opportunitiesRaymond james human health innovations conferenceDrug development summitWorld health organizationMeeting of the japanese diabetes societyTrophic communicationsPhepatology communicationsClinical development updates